Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, Status and Forecast 2019-2025

The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.

The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.

In 2018, the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Human Immunodeficiency Virus (HIV)-1 Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Human Immunodeficiency Virus (HIV)-1 Therapeutics development in United States, Europe and China.

The key players covered in this study
- AbbVie, Inc. (U.S.)
- Merck & Co., Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Boehringer Ingelheim GmbH (Germany)
- Genentech, Inc. (U.S.)
- Cipla, Inc. (India)

Market segment by Type, the product can be split into
- Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Entry and Fusion Inhibitors
- Protease Inhibitors (Pis)
- Integrase Inhibitors
- Coreceptor Antagonists

Market segment by Application, split into
- Hospitals
- Clinics
- Labs

Market segment by Regions/Countries, this report covers
- United States
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America

The study objectives of this report are:
- To analyze global Human Immunodeficiency Virus (HIV)-1 Therapeutics status, future forecast, growth opportunity, key market and key players.
- To present the Human Immunodeficiency Virus (HIV)-1 Therapeutics development in United States, Europe and China.
- To strategically profile the key players and comprehensively analyze their development plan and strategies.
- To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Human Immunodeficiency Virus (HIV)-1 Therapeutics are as follows:
- History Year: 2014-2018
- Base Year: 2018
- Estimated Year: 2019
- Forecast Year 2019 to 2025

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents:

Table of Contents
1 Report Overview
   1.1 Study Scope
   1.2 Key Market Segments
   1.3 Players Covered
   1.4 Market Analysis by Type
      1.4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
1.4.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
1.4.4 Entry and Fusion Inhibitors
1.4.5 Protease Inhibitors (PIs)
1.4.6 Integrase Inhibitors
1.4.7 Coreceptor Antagonists

1.5 Market by Application
- 1.5.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application (2014-2025)
- 1.5.2 Hospitals
- 1.5.3 Clinics
- 1.5.4 Labs

1.6 Study Objectives

1.7 Years Considered

2 Global Growth Trends
- 2.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size
- 2.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Growth Trends by Regions
  - 2.2.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Regions (2014-2025)
  - 2.2.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Regions (2014-2019)
- 2.3 Industry Trends
  - 2.3.1 Market Top Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Opportunities

3 Market Share by Key Players
- 3.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Manufacturers
  - 3.1.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Manufacturers (2014-2019)
  - 3.1.3 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players Head office and Area Served
- 3.3 Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Product/Solution/Service
- 3.4 Date of Enter into Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
- 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
- 4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2014-2019)

5 United States
- 5.1 United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2014-2019)
- 5.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players in United States
- 5.3 United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type
- 5.4 United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application

6 Europe
- 6.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players in Europe
- 6.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type
- 6.4 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application

7 China
- 7.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players in China
- 7.3 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type
- 7.4 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application

8 Japan
- 8.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players in Japan
- 8.3 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type
- 8.4 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application

9 Southeast Asia
- 9.1 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2014-2019)
- 9.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players in Southeast Asia
- 9.3 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type
- 9.4 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application

10 India
- 10.1 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2014-2019)
- 10.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players in India
- 10.3 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type
- 10.4 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application

11 Central & South America
- 11.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players in Central & South America
- 11.3 Central & South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type
- 11.4 Central & South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application

12 International Players Profiles
- 12.1 AbbVie, Inc.(U.S.)
  - 12.1.1 AbbVie, Inc.(U.S.) Company Details
  - 12.1.2 Company Description and Business Overview
  - 12.1.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
  - 12.1.4 AbbVie, Inc.(U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2014-
12.1.5 AbbVie, Inc. (U.S.) Recent Development

12.2 Merck & Co., Inc. (U.S.)
- 12.2.1 Merck & Co., Inc. (U.S.) Company Details
- 12.2.2 Company Description and Business Overview
- 12.2.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
- 12.2.4 Merck & Co., Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2014-2019)
- 12.2.5 Merck & Co., Inc. (U.S.) Recent Development

12.3 Bristol-Myers Squibb Company (U.S.)
- 12.3.1 Bristol-Myers Squibb Company (U.S.) Company Details
- 12.3.2 Company Description and Business Overview
- 12.3.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
- 12.3.4 Bristol-Myers Squibb Company (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2014-2019)
- 12.3.5 Bristol-Myers Squibb Company (U.S.) Recent Development

12.4 Boehringer Ingelheim GmbH (Germany)
- 12.4.1 Boehringer Ingelheim GmbH (Germany) Company Details
- 12.4.2 Company Description and Business Overview
- 12.4.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
- 12.4.4 Boehringer Ingelheim GmbH (Germany) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2014-2019)
- 12.4.5 Boehringer Ingelheim GmbH (Germany) Recent Development

12.5 Genentech, Inc. (U.S.)
- 12.5.1 Genentech, Inc. (U.S.) Company Details
- 12.5.2 Company Description and Business Overview
- 12.5.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
- 12.5.5 Genentech, Inc. (U.S.) Recent Development

12.6 Cipla, Inc. (India)
- 12.6.1 Cipla, Inc. (India) Company Details
- 12.6.2 Company Description and Business Overview
- 12.6.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
- 12.6.4 Cipla, Inc. (India) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2014-2019)
- 12.6.5 Cipla, Inc. (India) Recent Development

13 Market Forecast 2019-2025
- 13.1 Market Size Forecast by Regions
- 13.2 United States
- 13.3 Europe
- 13.4 China
- 13.5 Japan
- 13.6 Southeast Asia
- 13.7 India
- 13.8 Central & South America
- 13.9 Market Size Forecast by Product (2019-2025)

14 Analyst’s Viewpoints/Conclusions

15 Appendix
- 15.1 Research Methodology
  - 15.1.1 Methodology/Research Approach
    - 15.1.1.1 Research Programs/Design
    - 15.1.1.2 Market Size Estimation
    - 15.1.1.3 Market Breakdown and Data Triangulation
  - 15.1.2 Data Source
    - 15.1.2.1 Secondary Sources
    - 15.1.2.2 Primary Sources
- 15.2 Disclaimer